This meeting took place in 2017
Here are the related meetings in 2019:
HIV Vaccines (X7)
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
HIV Vaccines (C9)
Organizer(s) Andrew B. Ward, Penny L. Moore and Robin Shattock
March 26—30, 2017
Sheraton Steamboat Resort • Steamboat Springs, Colorado USA
Discounted Abstract Deadline: Nov 29, 2016
Abstract Deadline: Jan 10, 2017
Scholarship Deadline: Nov 29, 2016
Discounted Registration Deadline: Jan 24, 2017
Part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation.
Summary of Meeting:
Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.
View Meeting Program
Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.
View Meeting Program
Scholarships/Awards
NIAID - 1R13AI129592-01 Scholarship Recipients
Yoann AldonImperial College London, UK
Anna-Janina Behrens
University of Oxford, UK
Anne-Line Coolen
Laboratoire de Biologie Tissulaire et d’Ingénierie Thérapeutique, France
Alan D. Curtis
University of North Carolina at Chapel Hill, USA
Cailin Deal
Ragon Institute, USA
Adam Dingens
Fred Hutchinson Cancer Research Center, USA
Samantha Leigh Grimley
San Diego Biomedical Research Institute, USA
Alice Gutjahr
Groupe sur l'Immunité des Muqueuses et Agents Pathogènes, France
Hannah King
Henry M Jackson Foundation, USA
Dieter Mielke
Duke University, USA
David Peterhoff
University Regensburg, Germany
Murillo Silva
Massachusetts Institute of Technology, USA
Christian W. Thorball
École Polytechnique Fédérale de Lausanne, Switzerland
Alba Torrents de la Pena
Academic Medical Center Amsterdam, Netherlands
Hua Wang
Tsinghua University, China
Keystone Symposia Global Health Travel Award Recipients, funded by the Bill & Melinda Gates Foundation
Heena AggarwalAIIMS, India
Abdurrahman Ahmad
Ahmadu Bello University, Zaria, Nigeria
Oluwafemi David Ajayi
ABUAD Multi-System Hospital, Nigeria
Adeolu Oladayo Akinboro
Ladoke Akintola University of Technology, Nigeria
Abere Shiferaw Alemu
Haramaya University, Ethiopia
Michael Oluyemi Babalola
ADEKUNLE AJASIN UNIVERSITY, Nigeria
Abate Assefa Bashaw
University of Queensland Diamantina Institute, Australia
Liya Wassie Dubale
Armauer Hansen Research Institute, Ethiopia
Brhanu Teka Endallew
Addis Ababa University, Ethiopia
Anne Awuor Gumbe
University of Nairobi, IAVI, Kenya
Mohammad Uzzal Hossain
National Institute of Biotechnology, Bangladesh
Bartholomew Okechukwu Ibeh
National Biotechnology Development Agency, Nigeria
Vidya vijayan karuvan kandiyil
National Institute for Research in Tuberculosis, India
Paul Kato Kitandwe
Uganda Virus Research Institute, Uganda
Girum Tesfaye Kiya
Jimma University, Ethiopia
Sanjeev Kumar
All India Institute of Medical Sciences, India
Fredrick Lutwama
Uganda Virus Research Institute-International AIDS Vaccine Initiative, Uganda
Tshepiso Mbangiwa
Botswana Harvard AIDS Institute Partnership, Botswana
Randy George Mungwira
Blantyre Malaria Project, Malawi
Rose Nabatanzi
Makerere University College of Health Sciences, Uganda
Ogbonnaya Ogbu
Ebonyi State University, Nigeria
Funsho J. Ogunshola
University of KwaZulu-Natal, South Africa
Hannah Oluwayemisi Olawumi
College of Health Sciences, University of Ilorin, Nigeria
Olaniyi Onayemi
Obafemi Awolowo University, Nigeria
Semaria Solomon
St. Paul’s Hospital Millennium Medical College, Ethiopia
Waidi Folorunso SULE
Osun State University, Nigeria
Marius Belmondo Tincho
University of the Western Cape, South Africa
Lufina Tsirizani
University of Malawi, College of Medicine, Malawi
Nkiruka Rose Ukibe
Nnamdi Azikiwe University, Nigeria
Saheed Opeyemi Usman
APIN Public Health Initiatives, Nigeria
